Intra-arterial gemcitabine for unresectable pancreatic cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1504, 2005-01, pp. : 19-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparative Pharmacokinetics and Metabolic Pathway of Gemcitabine During Intravenous and Intra-arterial Delivery in Unresectable Pancreatic Cancer Patients

By Shamseddine Ali I.  

Clinical Pharmacokinetics, Vol. 44, Iss. 9, 2005-01 ,pp. : 957-967

Adis International

Access to resources Recommend Favorite

Erlotinib + gemcitabine of no value in pancreatic cancer

By  

Inpharma, Vol. 1, Iss. 1610, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Erlotinib + gemcitabine of no value in pancreatic cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 539, 2007-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Gemcitabine of no benefit after pancreatic cancer resection

By  

Inpharma, Vol. 1, Iss. 1628, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

UK NICE guidance on gemcitabine for pancreatic cancer

By  

Inpharma, Vol. 1, Iss. 1289, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite